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Background: Therapies that lower LDL-C often increase the proportion of small, LDL particles (Pattern B), which may be misinterpreted as a 
worsening of atherosclerotic CHD risk. Pre-treatment diagnostic vs post-treatment efficacy lipoprotein pattern analysis may have different clinical 
implications.
Methods: Hypercholesterolemic patients at high CHD risk were stabilized on atorvastatin (AT) 40 mg followed by randomization to ezetimibe (EZ) 
10 mg + AT 40 mg vs doubling of AT to 80 mg for 6 weeks. Vertical Auto Profile-II analysis was performed on the overall population, as well as on 
those grouped by baseline triglyceride (TG) level <150 mg/dL or ≥150 mg/dL.
Results: In the full data set and in the higher/lower TG subsets, the proportion of Pattern B increased with both treatments. Both EZ+AT and AT 
reduced LDL-C levels and decreased the cholesterol content of most LDL subfractions (LDL1-4). Together, the cholesterol content in the larger 
LDL1 and LDL2 subfractions was generally reduced more than in the smaller LDL3 and LDL4 subfractions together. Both treatments reduced apo B, 
reflecting a reduction in overall atherogenic lipoprotein particle number.
Conclusions: LDL-C lowering therapy may disproportionately reduce larger (more easily cleared) LDL particles, and thus increase Pattern B. A post-
treatment change to Pattern B alone may be misleading in assessing the efficacy of cholesterol lowering therapy. 
Pattern B (%) LDL1* LDL2* LDL3* LDL4* LDL-C† Apo B†
A80 mg
(N=222)
Baseline,
mg/dL (SD)
128/222 (57.7) 14.0 (6.5) 16.5 (12.1) 41.5 (13.0) 9.0 (7.4) 89.7 (16.0) 102.0 (18.5)
Week 6,
mg/dL (SD)
141/222 (63.5) 12.0 (4.7) 15.0 (10.2) 37.0 (13.0) 9.0 (7.4) 79.1 (19.9) 93.2 (20.0)
% change (SD) -- -10.5 (30.4) -16.5 (48.7) -10.0 (25.6) 0.0 (74.0) -11.0 (1.1) -7.7 (0.9)
A40 mg + EZ
(N=225)
Baseline,
mg/dL (SD)
127/225 (56.4) 14.0 (4.7) 17.0 (14.9) 38.0 (14.0) 9.0 (7.4) 88.6 (16.3) 101.1 (18.8)
Week 6,
mg/dL (SD)
147/225 (65.3) 10.0 (3.7) 13.0 (7.4) 29.0 (11.2) 8.0 (4.7) 64.1 (19.9) 82.5 (19.3)
% change (SD) -- -26.7 (27.5) -23.3 (48.1) -23.8 (21.9) 0.0 (65.9) -27.4 (1.1) -17.8 (0.9)
*Values presented as median and SD is robust standard deviation
†Values presented as mean (standard error), for LDL-C, N=279 for A80 mg and N=277 for A40 mg + EZ; and for Apo B, N=276 for A80 mg and 
N=275 for A40 mg + EZ
